INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED

被引：0
|
作者：
Allegretti, Jessica R.
McClure, Emma L.
Marcus, Jenna
Norton, Beth Ann
Hamilton, Matthew
Winter, Rachel
De Silva, Punyanganie
Friedman, Sonia
Korzenik, Joshua R.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1874
引用
收藏
页码：S461 / S461
页数：1
相关论文
共 50 条
  • [31] Infliximab for medical induction of remission in Crohn's disease
    Gordon, Morris
    Radford, Shellie J.
    Eldragini, Mohsen Ebrahim Abdelhamid Ali
    Darie, Ana-Maria
    Sinopoulou, Vassiliki
    Akobeng, Anthony K.
    Moran, Gordon William
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (11):
  • [32] Microinflammation in patients with Crohn's disease in clinical remission
    Maharshak, Nitsan
    Zilberman, Liaz
    Arbel, Yaron
    Shapira, Itzhak
    Berliner, Shlomo
    Arber, Nadir
    Dotan, Iris
    JOURNAL OF CROHNS & COLITIS, 2008, 2 (04): : 310 - 314
  • [33] Prediction of Sustained Remission After Discontinuation of Infliximab in Patients With Crohn's Disease
    Papamichail, Konstantinos
    Casteele, Niels Vande
    Hauenstein, Scott
    Princen, Fred
    Singh, Sharat
    Ferrante, Marc
    van Assche, Gert A.
    Rutgeerts, Paul J.
    Gils, Ann
    Vermeire, Severine
    GASTROENTEROLOGY, 2014, 146 (05) : S457 - S457
  • [34] Successful Dose De-Escalation of Infliximab in Rheumatoid Arthritis Patients with Stable Low Disease Activity and Treatment
    van der Maas, Aatke
    den Broeder, Alfons
    van den Hoogen, Frank H. J.
    Van Riel, Piet
    van den Bemt, Bart J. F.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S666 - S666
  • [35] Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's disease
    Ferrante, M.
    Van Steenbergen, S.
    Bian, S.
    Ballet, V.
    Vermeire, S.
    Van Assche, G.
    Gils, A.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S331 - S331
  • [36] Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply
    Chaparro, M.
    Gisbert, J. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (07) : 940 - 941
  • [37] SUCCESSFUL DOSE DE-ESCALATION TO ADALIMUMAB 40MG EVERY THREE WEEKS IN PATIENTS WITH CROHN'S DISEASE
    Ferrante, Marc
    Van Steenbergen, Sophie
    Bian, Sumin
    Ballet, Vera
    Vermeire, Severine
    Van Assche, Gert A.
    Gils, Ann
    GASTROENTEROLOGY, 2017, 152 (05) : S406 - S407
  • [38] Maintenance therapy with infliximab for paediatric Crohn's disease: impact on clinical remission and mucosal healing in Polish paediatric patients with severe Crohn's disease
    Kierkus, Jaroslaw
    Dadalski, Maciej
    Szymanska, Sylwia
    Szymanska, Edyta
    Wegner, Agnieszka
    Gorczewska, Monika
    Oracz, Grzegorz
    Woynarowski, Marek
    Ryzko, Jozef
    PRZEGLAD GASTROENTEROLOGICZNY, 2012, 7 (01): : 26 - 30
  • [39] Antimicrobial de-escalation in septic cancer patients: is it safe to back down?
    Alla Paskovaty
    Stephen M. Pastores
    Zivile Gedrimaite
    Natalie Kostelecky
    Elyn R. Riedel
    Susan K. Seo
    Intensive Care Medicine, 2015, 41 : 2022 - 2023
  • [40] Antimicrobial de-escalation in septic cancer patients: is it safe to back down?
    Paskovaty, Alla
    Pastores, Stephen M.
    Gedrimaite, Zivile
    Kostelecky, Natalie
    Riedel, Elyn R.
    Seo, Susan K.
    INTENSIVE CARE MEDICINE, 2015, 41 (11) : 2022 - 2023
12345